DNA Aptamer-Polymer Conjugates for Selective Targeting of Integrin α4β1⁺ T-Lineage Cancers.

ABSTRACT: Selective therapeutic targeting of T-cell malignancies is difficult due to the shared lineage between healthy and malignant T cells. Current front-line chemotherapy for these cancers is largely nonspecific, resulting in frequent cases of relapsed/refractory disease. The development of targeting approaches for effectively treating T-cell leukemia and lymphoma thus remains a critical goal for the oncology field. Here, we report the discovery of a DNA aptamer, named HR7A1, that displays low nanomolar affinity for the integrin α4β1 (VLA-4), a marker associated with chemoresistance and relapse in leukemia patients. After truncation of HR7A1 to a minimal binding motif, we demonstrate elevated binding of the aptamer to T-lineage cancer cells over healthy immune cells. Using cryo-EM and competitio

SUBMITTER: Cardle II 

PROVIDER: S-EPMC11995848 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature